Analysts’ Recent Ratings Updates for Quest Diagnostics (DGX)

A number of research firms have changed their ratings and price targets for Quest Diagnostics (NYSE: DGX):

• 2/22/2026 – Quest Diagnostics was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/14/2026 – Quest Diagnostics was upgraded by Wall Street Zen from “hold” to “buy”.
• 2/12/2026 – Quest Diagnostics had its price target raised by Mizuho from $210.00 to $235.00. They now have an “outperform” rating on the stock.
• 2/11/2026 – Quest Diagnostics had its price target raised by UBS Group AG from $190.00 to $210.00. They now have a “neutral” rating on the stock.
• 2/11/2026 – Quest Diagnostics had its price target raised by Truist Financial Corporation from $205.00 to $220.00. They now have a “hold” rating on the stock.
• 2/11/2026 – Quest Diagnostics was given a new $220.00 price target by Evercore Inc.
• 2/11/2026 – Quest Diagnostics was given a new $219.00 price target by Robert W. Baird.
• 2/11/2026 – Quest Diagnostics had its price target raised by Barclays PLC from $210.00 to $225.00. They now have an “overweight” rating on the stock.
• 2/10/2026 – Quest Diagnostics had its price target raised by Jefferies Financial Group Inc. from $215.00 to $220.00. They now have a “buy” rating on the stock.
• 2/10/2026 – Quest Diagnostics had its price target raised by Citigroup Inc. from $190.00 to $215.00. They now have a “neutral” rating on the stock.
• 1/30/2026 – Quest Diagnostics was upgraded by Barclays PLC from “equal weight” to “overweight”. They now have a $210.00 price target on the stock.
• 1/25/2026 – Quest Diagnostics was downgraded by Wall Street Zen from “buy” to “hold”.
• 1/17/2026 – Quest Diagnostics was upgraded by Wall Street Zen from “hold” to “buy”.

Quest Diagnostics Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 20th. Investors of record on Monday, April 6th will be given a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a yield of 1.6%. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.80. The ex-dividend date is Monday, April 6th. Quest Diagnostics’s payout ratio is currently 36.57%.

Insiders Place Their Bets

In related news, SVP Michael E. Prevoznik sold 1,111 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $204.83, for a total value of $227,566.13. Following the transaction, the senior vice president directly owned 38,371 shares of the company’s stock, valued at approximately $7,859,531.93. This trade represents a 2.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Catherine T. Doherty sold 1,433 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $204.83, for a total value of $293,521.39. Following the completion of the sale, the executive vice president owned 68,402 shares in the company, valued at $14,010,781.66. This represents a 2.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 9,164 shares of company stock valued at $1,872,363. Company insiders own 8.16% of the company’s stock.

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.